Skip to content

Omega 3 on fatty liver

The efficacy of Omega3 in treatment of Non-Alcoholic Fatty Liver Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013052313427N1
Enrollment
50
Registered
2013-09-22
Start date
2012-12-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty (change of) liver. Nonalcoholic fatty liver disease (NAFLD)

Interventions

Intervention group get Omega3 2 gram per day (cap 1000mg (EPA 180: DHA 120)) for 3 months with other treatment have given to control group. Control group: increase activity, diet, Vit E, Liver support
Treatment - Drugs

Sponsors

Fasa University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patient who diagnosed as fatty liver disease by increase in ALT and AST and liver ultrasonography with 4 criteria of sonography added to intervention.The patient who hasn't sign the permission form, or drink ethanol more than 20 gram in a day or take some drugs that cause of fatty liver such as steroids,sterogen,amiodaron,tamoxifen in 6 month ago and patient who has Hepatit B and C,auto immune hepatitis, wilson, hemachromatosis, decrease of alpha-1-antitripsin or sever disease such as heart, liver, psychology disease was eliminated.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fatty liver. Timepoint: Before intervention, 3 months after intervention. Method of measurement: AST, ALT(liver enzymes).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Kargar

Fasa University of Medical Sciences

aminkargar5@yahoo.com+98 73 1222 0995

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026